Kavar Capital Partners Group’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $614K | Sell |
25,497
-1,240
| -5% | -$32.4K | 0.08% | 120 |
|
|
2026
Q1 | $751K | Sell |
26,737
-197
| -0.7% | -$5.25K | 0.09% | 116 |
|
|
2025
Q4 | $671K | Sell |
26,934
-2,495
| -8% | -$62.9K | 0.09% | 110 |
|
|
2025
Q3 | $750K | Sell |
29,429
-500
| -2% | -$12.3K | 0.1% | 112 |
|
|
2025
Q2 | $725K | Sell |
29,929
-4,181
| -12% | -$97.5K | 0.1% | 114 |
|
|
2025
Q1 | $864K | Buy |
34,110
+50
| +0.1% | +$1.31K | 0.14% | 97 |
|
|
2024
Q4 | $904K | Hold |
34,060
| – | – | 0.15% | 95 |
|
|
2024
Q3 | $986K | Sell |
34,060
-2,460
| -7% | -$71.8K | 0.16% | 95 |
|
|
2024
Q2 | $1.02M | Hold |
36,520
| – | – | 0.18% | 90 |
|
|
2024
Q1 | $1.01M | Sell |
36,520
-11,096
| -23% | -$308K | 0.19% | 89 |
|
|
2023
Q4 | $1.37M | Buy |
47,616
+20,158
| +73% | +$609K | 0.15% | 89 |
|
|
2023
Q3 | $911K | Sell |
27,458
-5,028
| -15% | -$178K | 0.2% | 89 |
|
|
2023
Q2 | $1.19M | Buy |
32,486
+80
| +0.2% | +$3.11K | 0.25% | 82 |
|
|
2023
Q1 | $1.32M | Sell |
32,406
-2,184
| -6% | -$94.3K | 0.29% | 77 |
|
|
2022
Q4 | $1.77M | Sell |
34,590
-16
| -0% | -$767 | 0.41% | 65 |
|
|
2022
Q3 | $1.51M | Sell |
34,606
-500
| -1% | -$24.3K | 0.39% | 68 |
|
|
2022
Q2 | $1.84M | Buy |
35,106
+581
| +2% | +$29.6K | 0.43% | 64 |
|
|
2022
Q1 | $1.79M | Sell |
34,525
-1,000
| -3% | -$51.9K | 0.39% | 68 |
|
|
2021
Q4 | $2.1M | Sell |
35,525
-850
| -2% | -$42.1K | 0.44% | 63 |
|
|
2021
Q3 | $1.56M | Buy |
36,375
+309
| +0.9% | +$13.7K | 0.36% | 72 |
|
|
2021
Q2 | $1.41M | Sell |
36,066
-1,673
| -4% | -$65.1K | 0.34% | 80 |
|
|
2021
Q1 | $1.37M | Buy |
37,739
+494
| +1% | +$17.5K | 0.37% | 73 |
|
|
2020
Q4 | $1.37M | Sell |
37,245
-1,405
| -4% | -$51.5K | 0.39% | 67 |
|
|
2020
Q3 | $1.35M | Buy |
38,650
+105
| +0.3% | +$3.68K | 0.45% | 63 |
|
|
2020
Q2 | $1.2M | Buy |
38,545
+2,812
| +8% | +$95.5K | 0.46% | 63 |
|
|
2020
Q1 | $1.11M | Sell |
35,733
-5,153
| -13% | -$176K | 0.53% | 62 |
|
|
2019
Q4 | $1.52M | Buy |
40,886
+1,181
| +3% | +$42.1K | 0.56% | 59 |
|
|
2019
Q3 | $1.35M | Buy |
39,705
+1,581
| +4% | +$57.5K | 0.53% | 62 |
|
|
2019
Q2 | $1.57M | Buy |
38,124
+185
| +0.5% | +$7.35K | 0.62% | 56 |
|
|
2019
Q1 | $1.53M | Buy |
37,939
+625
| +2% | +$25K | 0.68% | 56 |
|
|
2018
Q4 | $1.54M | Buy |
37,314
+2,846
| +8% | +$118K | 0.83% | 52 |
|
|
2018
Q3 | $1.44M | Buy |
34,468
+158
| +0.5% | +$6.08K | 0.71% | 59 |
|
|
2018
Q2 | $1.18M | Hold |
34,310
| – | – | 0.59% | 60 |
|
|
2018
Q1 | $1.16M | Hold |
34,310
| – | – | 0.6% | 60 |
|
|
2017
Q4 | $1.18M | Sell |
34,310
-1,844
| -5% | -$62.9K | 0.63% | 60 |
|
|
2017
Q3 | $1.23M | Buy |
36,154
+4,743
| +15% | +$152K | 0.67% | 61 |
|
|
2017
Q2 | $1M | Hold |
31,411
| – | – | 0.54% | 66 |
|
|
2017
Q1 | $1.02M | Buy |
31,411
+6,020
| +24% | +$190K | 0.57% | 66 |
|
|
2016
Q4 | $782K | Buy |
25,391
+3,057
| +14% | +$93.3K | 0.49% | 69 |
|
|
2016
Q3 | $718K | Sell |
22,334
-659
| -3% | -$22K | 0.46% | 72 |
|
|
2016
Q2 | $768K | Buy |
22,993
+606
| +3% | +$19.3K | 0.49% | 71 |
|
|
2016
Q1 | $630K | Buy |
22,387
+407
| +2% | +$11.6K | 0.42% | 77 |
|
|
2015
Q4 | $673K | Hold |
21,980
| – | – | 0.43% | 74 |
|
|
2015
Q3 | $655K | Sell |
21,980
-331
| -1% | -$10.6K | 0.46% | 70 |
|
|
2015
Q2 | $709K | Sell |
22,311
-190
| -0.8% | -$6.19K | 0.48% | 68 |
|
|
2015
Q1 | $743K | Sell |
22,501
-60
| -0.3% | -$1.91K | 0.63% | 62 |
|
|
2014
Q4 | $667K | Buy |
22,561
+617
| +3% | +$17.7K | 0.52% | 78 |
|
|
2014
Q3 | $616K | Sell |
21,944
-199
| -0.9% | -$5.58K | 0.53% | 81 |
|
|
2014
Q2 | $624K | Sell |
22,143
-264
| -1% | -$7.53K | 0.53% | 83 |
|
|
2014
Q1 | $682K | Sell |
22,407
-1,057
| -5% | -$31.5K | 0.56% | 75 |
|
|
2013
Q4 | $681K | Buy |
+23,464
| New | +$683K | 0.61% | 68 |
|
Other funds holding PFE
Kavar Capital Partners Group's PFE Position: Q2 2026 in Review
Kavar Capital Partners Group reduced its Pfizer (PFE) stake by 4.6% in Q2 2026, selling an estimated $32.4K and leaving 25,497 shares worth $614K. The position accounts for 0.08% of the portfolio, ranked #120.
Kavar Capital Partners Group first reported a position in PFE in Q4 2013 and has held it in 51 quarters since. The position peaked at $2.1M in Q4 2021. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Kavar Capital Partners Group held 25,497 shares of Pfizer worth $614K as of Q2 2026.
- Kavar Capital Partners Group sold 1,240 Pfizer shares in Q2 2026, an estimated $32.4K.
- Pfizer made up 0.08% of Kavar Capital Partners Group's portfolio in Q2 2026, its #120 holding.
- Kavar Capital Partners Group first reported a position in Pfizer in Q4 2013 and has held it in 51 quarters since.
- Kavar Capital Partners Group's Pfizer position peaked at $2.1M in Q4 2021.
- 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Kavar Capital Partners Group's 13F filing for Q2 2026, filed 20 Jul 2026.